Drug Type Mesenchymal stem cell therapy |
Synonyms Adipose-derived allogenic stem cell therapy - TiGenix NV, eASC - TiGenix, CX 611 + [1] |
Target- |
Mechanism Cell replacements, Immunomodulators, Inflammation mediator inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Start Date30 Jan 2017 |
Sponsor / Collaborator Tigenix SAU [+3] |
Start Date01 Jan 2012 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pneumonia, Bacterial | Phase 2 | BE | 30 Jan 2017 | |
Pneumonia, Bacterial | Phase 2 | ES | 30 Jan 2017 | |
Sepsis | Phase 2 | GB | 18 Mar 2016 | |
Rheumatoid Arthritis | Phase 2 | ES | 31 Mar 2011 | |
Drug-Related Side Effects and Adverse Reactions | Phase 1 | ES | 01 Jan 2012 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1/2 | 84 | Placebo | fiqqbuwtil(yiesgntotw) = ecswykiwws vjwxqzawlu (lnxkimgzua, yyzuxwlmvc - fgakmxcmeg) View more | - | 06 Apr 2022 |